Skadden, Shibolet, Deloitte and IATI (Israel Advanced Technology Industries) held a June 3 panel discussion, “U.S. IPOs Revealed: A Preview for Israeli Life Sciences Companies,” focusing on whether Israeli life sciences companies should be on the public markets. Panelists included Skadden partners Andrea Nicolas and Yossi Vebman; Shibolet partners Lior Aviram, Ofer Ben-Yehuda and Amir Iliescu; Deloitte partner Sharon Cohen; Foamix Pharmaceuticals founders Meir Eini and Dov Tomarkin; and Trendlines Chairman and CEO Todd Dollinger. They discussed the practical, legal and accounting-related considerations that Israeli life sciences companies should contemplate when deciding on going public.
Skadden, Arps, Slate, Meagher & Flom LLP and Affiliates